Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1Phase 3 1

Status

Completed 5Terminated 2Active not recruiting 2Recruiting 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Breast 1

Conditions

Melanoma 2Psoriasis 1Osteoarthritis 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Autoimmune Diseases 1Arthritis, Rheumatoid 1

Interventions

pembrolizumab 244Nivolumab 140Cisplatin 135Cyclophosphamide 134Paclitaxel 113Carboplatin 108Gemcitabine 98Radiotherapy 83Dexamethasone 83Docetaxel 77atezolizumab 68Ipilimumab 68Doxorubicin 62Fluorouracil 60Blood Specimen Collection 58Bevacizumab 58fludarabine 54Rituximab 54Etoposide 53Oxaliplatin 52Surveys and Questionnaires 49Lenalidomide 49Prednisone 47Standard of Care 45Magnetic Resonance Spectroscopy 45Cetuximab 44Capecitabine 44lenvatinib 43Radiosurgery 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Docosahexaenoic Acids × 1 year × Clear all
NCT01881048 2026-01-29

Window of Opportunity Study Targeting the Inflammatory Milieu

University of Colorado, Denver

Phase EARLY_PHASE1 Completed
42 enrolled
Breast

Breast Neoplasms

NCT01351805 2025-12-03

VITAL

Brigham and Women's Hospital

Phase NA Completed
25,871 enrolled 15 charts

Arthritis, Rheumatoid, Autoimmune Diseases, Osteoarthritis, Psoriasis

NCT00244816 2025-10-23

Taxoprexin® Treatment for Advanced Eye Melanoma

American Regent, Inc.

Phase 2 Completed
22 enrolled
Dermatologic

Melanoma

NCT00249262 2025-09-26

Taxoprexin Treatment for Advanced Skin Melanoma

American Regent, Inc.

Phase 2 Completed
30 enrolled
Dermatologic

Melanoma

NCT00243867 2025-08-01

Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer

American Regent, Inc.

Phase 3 Completed
518 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡